Metraipolis › archive › dc_32b49bf5f6f2

The safety and immunogenicity of inactivated rotavirus vaccine delivered by a dissolving microneedle patch in rats — Europe PMC PMID:40936299

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40936299
DOI
10.1080/21645515.2025.2555700
License (as archived)
CC0-1.0
Archived
2026-10-08T01:06:27.766Z
SHA-256 of the archived text
630f111a3bf0fe8aebee87b1635a2de2615d52aff3cd6c56ee6f9746f80e9a67
Stable URL of this page
https://metraipolis.com/documento/dc_32b49bf5f6f2

How to cite

The safety and immunogenicity of inactivated rotavirus vaccine delivered by a dissolving microneedle patch in rats — Europe PMC PMID:40936299 — Europe PMC (en), https://europepmc.org/article/MED/40936299 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_32b49bf5f6f2 (Metraipolis archive dc_32b49bf5f6f2, sha256 630f111a3bf0fe8aebee87b1635a2de2615d52aff3cd6c56ee6f9746f80e9a67)
BibTeX
@misc{dc32b49bf5f6f2,
  title = {The safety and immunogenicity of inactivated rotavirus vaccine delivered by a dissolving microneedle patch in rats — Europe PMC PMID:40936299},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40936299},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_32b49bf5f6f2; sha256 630f111a3bf0fe8aebee87b1635a2de2615d52aff3cd6c56ee6f9746f80e9a67},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/40936299. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

The development of dissolving microneedle patches (dMNPs) for inactivated rotavirus vaccine (IRV) requires concurrent evaluation of safety parameters, including local and systemic toxicity and immune response characteristics. The aim of this study is to evaluate the toxicological safety profiles and immunogenic potential of IRV dMNPs in rats through assessment of systemic toxicity, local responses, and neutralizing activities. IRV dMNPs were examined for stability under different storage conditions (5 ± 3°C and 25 ± 2°C) for up to 24 months. Toxicology assessment included clinical observation, body weight monitoring, food consumption, hematology, clinical chemistry, organ weight analysis, and histopathological examination. Local tolerance was evaluated using Draize scoring and microscopic examination of the administration sites. Immunogenicity was evaluated by measuring neutralizing activities in sera against homotypic and heterotypic RV strains. The potency of IRV dMNPs was found stable for at least 24 months at 5 ± 3°C, and for 12 months at 25 ± 2°C. Toxicological evaluation showed no adverse systemic effects, with all clinical pathology parameters remaining within normal ranges. Local dermal reactions were mild (mean Draize scores <1.5) and subsided within 48 h. Histopathology showed only low to mild inflammatory changes at the application sites, with complete resolution by the end of study (day 57). Immunological analysis showed robust and cross-reactive neutralizing activities against homotypic and heterotypic RV strains in sera of rats. IRV dMNPs showed strong stability and an excellent safety profile while also inducing robust and extensive immune responses, supporting its further development as an alternate IRV platform.

Tema degli esploratori: ricerca e scienza aperta (ricerca Europe PMC «preprint», solo open access).
Pubblicazione: Human vaccines & immunotherapeutics, 2025 (prima pubblicazione 2025-09-11).
Identificativi: PMID 40936299 · PMCID PMC12439544 · DOI 10.1080/21645515.2025.2555700.
Parole chiave degli autori: Immunogenicity; Rotavirus; toxicology; Inactivated Rotavirus Vaccine; Dissolving Microneedle Patch.
Descrittori MeSH principali: Rotavirus Infections; Rotavirus Vaccines; Immunogenicity, Vaccine.
Pagina: https://europepmc.org/article/MED/40936299 — https://doi.org/10.1080/21645515.2025.2555700. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-08T00:45:51.903Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.